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Abstract
Background: We reviewed outcomes of patients with loco-regionally recurrent (LRR) or new primary (NP)
squamous cell carcinoma of the head and neck (SCCHN) treated at our institution with reirradiation (RRT).
Methods: Patients received definitive RRT (DRRT) or post-operative RRT following salvage surgery (PRRT) from 2003
to 2011. Measured survival outcomes included loco-regional relapse free survival (LRFS) and overall survival (OS).
Results: Among 81 patients (PRRT, 42; DRRT, 39), median PRRT and DRRT doses were 60 Gy (12–70 Gy) and 69.6 Gy
(48–76.8 Gy). The majority of patients received IMRT-based RRT (n = 77, 95 %). With median follow-up of
78.1 months (95 % CI, 56–96.8 months), 2-year OS was 53 % with PRRT and 48 % with DRRT (p = 0.12); 23 % of
patients were alive at last follow-up. LRFS at 2 years was 60 %, and did not differ significantly between PRRT and
DRRT groups. A trend toward inferior LRFS was noted among patients receiving chemotherapy with RRT versus RRT
alone (p = 0.06). Late serious toxicities were uncommon, including osteoradionecrosis (2 patients) and carotid artery
bleeding (1 patient, non-fatal).
Conclusions: OS of PRRT- and DRRT-treated patients in this series appears superior to the published literature. We
used IMRT for the majority of patients, in contrast to several series and trials previously reported, which may
account in part for this difference. Future studies should seek to improve outcomes among patients with LRR/NP
SCCHN via alternative therapeutic modalities such as proton radiotherapy and by incorporating novel systemic
agents.
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Background
Although 5-year survival rates for oral cavity and phar-
ynx cancer have improved significantly since the 1970s
(53 % 1975–1977 versus 66 % 2004–2010, p < 0.05) [1],
this improvement likely is due to an increase in
favorable-prognosis Human Papilloma Virus-associated
oropharynx cancers rather than the development of
more effective treatment. In contrast, the five year sur-
vival rate for laryngeal cancer has not improved since
the 1970s. A substantial percentage of patients with
loco-regionally advanced squamous cell carcinomas of
the head and neck (SCCHN) continue to experience dis-
ease recurrence after upfront surgery and/or radiation
therapy. An estimated 17–33 % of loco-regionally ad-
vanced SCCHN patients develop loco-regional recur-
rences following definitive radiotherapy, and new
SCCHN primaries in previously radiated volumes may
develop at a rate of 1 % per year [2–4].
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Curative-intent treatment options for patients with
loco-regionally recurrent or new primary SCCHN (LRR/
NP SCCHN) include surgical salvage alone, surgery
followed by radiotherapy with or without chemotherapy,
or radiotherapy with or without chemotherapy for non-
surgical candidates. Experience with reirradiation (RRT)
for LRR/NP SCCHN has been reported by several
groups and evaluated in prospective trials. RRT confers
increased risk of serious side effects, including but not
limited to myelopathy, osteoradionecrosis of the man-
dible (ORN), tracheo-esophageal fistulae and fatal ca-
rotid artery hemorrhage. Despite these risks, most
studies show that RRT cures a modest percentage of
LRR/NP SCCHN patients with acceptable rates of ser-
ious toxicities [5].
To better understand the outcomes of our LRR/NP
SCCHN patients treated at Mayo Clinic with RRT, we
conducted a retrospective review. We sought to under-
stand what disease and treatment-related factors may be
associated with survival outcomes in this patient popula-
tion. We included only patients treated in the contem-
porary era, when intensity modulated radiation therapy
(IMRT) was used for most patients.
Methods
We retrospectively reviewed the medical records of
LRR/NP SCCHN patients treated with curative-intent
definitive (DRRT) or post-operative reirradiation (PRRT)
with or without chemotherapy from January 1, 2003
through December 31, 2011. All patients were treated at
Mayo Clinic sites in Minnesota, Florida or Arizona. The
review was approved by the Mayo Clinic Institutional
Review Board.
Primary aims were to determine patient characteris-
tics, doses and techniques of radiotherapy used, the
number of patients given chemotherapy and type of
chemotherapy given, and to calculate survival outcomes
including loco-regional relapse free survival (LRFS), dis-
tant metastasis free survival (DMFS), and the overall sur-
vival (OS) of LRR/NP SCCHN patients treated with RRT
at our institution over this time period. We included
only patients with a histologically confirmed diagnosis of
LRR/NP SCCHN and who had undergone prior curative
intent radiation (+/− surgery and/or chemotherapy). Pa-
tients with new primary non-squamous cell cancers of
the head and neck undergoing RRT and those treated
with RRT at centers outside of Mayo Clinic were not in-
cluded. We did not include patients treated with RRT
for palliative purposes.
Patients selected for RRT at Mayo Clinic underwent
clinical and radiologic staging, with distant metastases
excluding patients from consideration of curative-intent
RRT. All patients had localized disease, and previous ra-
diation records were carefully reviewed. Patients were
more than 12 months from prior course of radiation
therapy. All patients underwent CT-based treatment
planning with thermoplastic mask immobilization. The
majority of patients were treated with IMRT. Minimum
target volume included gross disease plus margin in the
DRRT patients. Cumulative spinal cord doses were kept
below 60 Gy.
Statistical analyses were performed using JMP version
11. Demographic and treatment data were tabulated by
treatment group (PRRT versus DRRT), with differences
between subgroups defined by categorical factors deter-
mined using the chi-squared test of independence and
one way analysis of variance for subgroups defined by
continuous variables. We used Kaplan-Meier methods to
calculate median follow-up time from diagnosis of LRR/
NP SCCHN, median time from date of first primary
SCCHN to LRR/NP SCCCHN, median OS for the entire
group and by treatment method (PRRT verus DRRT),
and median LRFS and DMFS. LRFS and DMFS were
measured from the date of completing RRT to date of
diagnosis of loco-regional recurrence or distant metasta-
ses. OS was measured from date of diagnosis of LRR/NP
SCCHN to date of death or last follow-up. Patients were
considered censored at last follow-up date if the patient
did not experience the event of interest (local-regional
relapse, distant relapse or death). Cox proportional haz-
ards model was used to determine hazard ratios for
LRFS, DMFS and OS by subgroups as follows: LRR ver-
sus NP SCCHN, age < or ≥ 60 years at diagnosis of LRR/
NP SCCHN, sex, tobacco abuse (< or ≥ 20 pack-years),
PRRT versus DRRT, time since primary SCCHN (< or ≥
24 months), use of chemotherapy with RRT, use of plat-
inum versus cetuximab with RRT, and use of IMRT ver-
sus other technique with RRT. A p value less than 0.05
was considered significant.
Results
We identified 81 patients (61 male, 20 female); 59 pa-
tients had LRR; 22 NP. Treatment included salvage sur-
gery with PRRT (42 patients); 39 patients received
DRRT. Table 1 shows patient demographics and other
disease-related data from the cohort. There were no sig-
nificant differences between PRRT- and DRRT-treated
patients with respect to original primary site, recurrence
site or new primary site. Human Papilloma Virus (HPV)
status was not routinely tested, and therefore we were
unable to perform any subgroup analyses based on this
prognostic factor.
Table 2 provides details about concurrent chemother-
apy with RRT and the radiotherapy techniques used both
for primary radiotherapy (where such information was
available in the medical record) and RRT. The median
total dose of prior radiation for the cohort was 66 Gy
(26.4–79.2 Gy). Use of chemotherapy with the first
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Table 1 Demographics and disease-related information by treatment group among 81 LRR/NP SCCHN patients undergoing
reirradiation at Mayo Clinic
Characteristic Surgery/PRRT n (%) DRRT n (%) P
# patients 42 (52) 39 (48)
Sex
Male 34 (81) 27 (69) 0.22
Female 8 (19) 12 (31)
Age, years
Median (range) 61 (34–83) 65 (36–83) 0.23
Original primary site
BOT/OP 10 (24) 14 (36) 0.23
OC/FOM 7 (17) 3 (8)
Larynx 15 (36) 17 (44)
Sinus 2 (5) 0 (0)
Other 4 (9) 4 (10)
Unknown primary 4 (9) 1 (2)
Relapse at primary site 17 (41) 11 (28)
BOT/OP 2 (12) 5 (46) 0.20
OC/FOM 3 (18) 2 (18)
Larynx/stoma 10 (58) 4 (36)
Sinus 1 (6) 0 (0)
Nasal cavity 1 (6) 0 (0)
Relapse at other site, not considered NP 14 (33) 17 (44)
BOT/OP 0 (0) 1 (6) 0.06
OC/FOM 1 (7) 0 (0)
Sinus 1 (7) 0 (0)
Nasopharynx 1 (7) 1 (6)
Contra. Neck 7 (50) 2 (11)
Ipsilat. Neck 4 (29) 10 (59)
Supraclavicular 0 (0) 1 (6)
Trachea 0 (0) 2 (11)
NP site 11 (26) 11 (28)
BOT/OP 2 (18) 7 (64) 0.07
OC/FOM 2 (18) 0 (0)
Larynx 5 (45) 2 (18)
Sinus 1 (9) 0 (0)
Nasal cavity 1 (9) 0 (0)
Nasopharynx 0 (0) 2 (18)
Mean LRR/NP size, cm (SD) 3.4 (1.48) 3.2 (0.98) 0.785
Median # positive lymph nodes (range) 1 (0–9) N/A
LRR/NP Grade
2 6 (16) 2 (9) 0.19
3 20 (56) 18 (78)
4 10 (28) 3 (13)
# ECE 19 (45) N/A
# LVI 10 (24) N/A
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course of radiation could not be determined from the re-
cords of 57 patients. In the RRT setting, almost all
DRRT-treated patients received 70 Gy or more, whereas
most PRRT-treated patients received at least 60 Gy. A
majority of patients in both DRRT- and PRRT-treated
groups received concurrent chemotherapy. Cisplatin as a
radiosensitizing agent was given to more PRRT patients
than DRRT patients, for whom a majority received either
cetuximab or carboplatin. In the PRRT group, more pa-
tients with positive margins received chemotherapy (9/
11, 82 %) than patients with negative margins (11/21,
47.6 %, p = 0.05). Of patients with 1 or more lymph
nodes involved, 21 (84 %) received chemotherapy.
The median follow-up time for the entire cohort from
date of LRR/NP diagnosis was 78.1 months (95 % CI,
56–96.8 months). Five patients were lost-to-follow-up
(not seen for ≥ 2 years at time of analysis with no re-
corded date of death). Median time from date of first
primary SCCHN to LRR/NP SCCHN was 33.2 months
(95 % CI, 25–48.6 months). No significant difference in
time from date of first primary SCCHN to LRR/NP
SCCHN was found between the PRRT and DRRT
Table 1 Demographics and disease-related information by treatment group among 81 LRR/NP SCCHN patients undergoing
reirradiation at Mayo Clinic (Continued)
# perineural invasion 10 (24) N/A
# positive margins 11 (26) N/A
Tobacco use
0 6 (14) 8 (21) 0.77
<20 PY 6 (14) 5 (13)
≥20 OY 25 (60) 22 (56)
UTQ 5 (12) 4 (10)
Alcohol abuse by history 14 (33) 10 (26) 0.41
BOT base of tongue, DRRT definitive reirradiation therapy, ECE extracapsular extension, FOM floor of mouth, LVI lymphovascular invasion, LRR loco-regionally
recurrent, NP new primary, OC oral cavity, OP oropharynx, PRRT post-operative reirradiation therapy, PY pack-year, SD standard deviation, UTQ unable to quantify
Table 2 Chemotherapy and radiotherapy data for LRR/NP SCCHN patients undergoing reirradiation at Mayo Clinic
Surgery/PRRT DRRT P
RRT + concurrent chemotherapy 28 (67) 32 (82) 0.11
Type
Cisplatin 17 (61) 7 (22) 0.002
Cetuximab 8 (29) 11 (34)
Cisplatin + cetuximab 0 3 (9)
Carboplatin 1 (3) 5 (16)
Other 2 (7) 6 (19)
Median primary radiotherapy dose 66 Gy (50–72 Gy) 66 Gy (26.4–79.2) 0.62
Median RRT dose 60 Gy (12–70 Gy) 69.6 Gy (48–76.8 Gy) <0.0001
RRT dose
< 60 Gy 11 (26) 1 (3) -
≥ 60 to < 70 Gy 25 (60) 8 (20)
≥ 70 Gy 6 (14) 30 (77)
Primary radiotherapy technique
IMRT 22 (52) 11 (28) 0.95
3D conformal 13 (31) 18 (46)
No information 7 (17) 10 (26)
RRT technique
IMRT 36 (86) 38 (97) 0.08
IMRT/IORT 3 (7) 0
3D conformal 3 (7) 1 (3)x
DRRT definitive reirradiation therapy, IMRT intensity modulated radiation therapy, IORT intra-operative radiation therapy, PRRT post-operative reirradiation therapy,
RRT reirradiation
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patients (median time 28.2 months, 95 % CI, 20–
48.6 months for PRRT, versus 38.2 months, 95 % CI,
25.1–78.2 months for DRRT, p = 0.99).
OS at 2 years for the entire cohort was 50 %, with a me-
dian OS of 22.2 months (95 % CI, 17–29.8 months). We
found no difference in OS between PRRT patients (53 %
at 2 years, median OS 28.6 months, 95 % CI, 14.1–
61.6 months) versus DRRT patients (48 % at 2 years, me-
dian OS 22.2 months, 95 % CI, 12.7–32.1 months, p =
0.12, Fig. 1). Neither concurrent chemotherapy nor RRT
technique affected OS on univariate analysis (Table 3).
Total RRT dose (≥70 Gy versus < 70 Gy) did not impact
OS of the DRRT-treated group. However, a trend toward
inferior OS among PRRT patients who did not receive at
least 60 Gy compared to PRRT-treated patients receiving
at least 60 Gy was observed (10.2 months, 95 % CI, 2.3–
84.1 months versus 35.3 months, 95 % CI, 19.8–
61.6 months, p = 0.08).
LRFS at 2 years for the entire cohort was 60 %, with a
median LRFS following RRT of 54.7 months (95 % CI,
24.5 months – NR). Loco-regional recurrences following
RRT occurred in 34 patients (42 %), 28 (82 %) of which
occurred within 2 years. Figure 2 shows no significant
difference in loco-regional recurrence free survival ac-
cording to PRRT or DRRT treatment groups. Overall,
most loco-regional recurrences were within the RRT
treatment volume (n = 21, 62 %). By treatment group, 19
DRRT patients developed loco-regional recurrence, 13
(68 %) of which were in-field, and 15 PRRT patients de-
veloped loco-regional recurrence, 8 (53 %) of which were
in-field (p = 0.37 for in-field recurrences with DRRT ver-
sus PRRT). Use of IMRT with RRT did not impact time
to loco-regional recurrence.
DMFS at 2 years for the entire cohort was 53 %, with
a median DMFS following RRT of 27.4 months (95 %
CI, 18.9–34.5 months). No significant difference in
DMFS between PRRT and DRRT-treated patients was
observed (median 32 months, 95 % CI, 19.7–49.1 months
with PRRT versus 21.6 months, 95 % CI, 10.2–
32.8 months with DRRT, p = 0.11). Distant metastases
developed in 18 patients (22 %), with 15 of these 18 pa-
tients (83 %) developing distant metastases within 2 years
of completing RRT. Concurrent chemotherapy had no
impact on DMFS on univariate analysis (Table 3).
Univariate analysis revealed no statistically significant
differences in LRFS, DMFS or OS based on any of the
variables analyzed except for receipt of platinum chemo-
therapy with RRT and concurrent chemotherapy/RRT,
both associated significantly with LRFS (Table 3). Con-
current chemotherapy with RRT was associated with in-
ferior LRFS, whereas platinum chemotherapy versus
cetuximab with RRT was associated with improved
LRFS.
Acute toxicity mostly consisted of radiation dermatitis
and mucositis (71 of 81 patients, 88 %). Gastrointestinal
toxicities (nausea, vomiting and/or diarrhea) were
reported in 13 patients (16 %). Among surviving pa-
tients, 2 cases of ORN (10 %) and 1 non-fatal carotid ar-
tery bleeding aneurysm, successfully treated with
embolization (5 %), were reported, with no reported
Fig. 1 Kaplan-Meier plot of overall survival among LRR/NP SCCHN patients treated with DRRT versus PRRT
Curtis et al. Radiation Oncology  (2016) 11:55 Page 5 of 10
Table 3 Univariate analyses of survival outcomes by patient and treatment-related factors
Overall Survival, HR
(95 % CI)
Time to loco-regional recurrence, mos
(95 % CI)
Time to distant metastases, mos
(95 % CI)
LRR vs. NP SCCHN 0.84 (0.49–1.49) 1.05 (0.51–2.38) 0.99 (0.58–1.77)
P = 0.53 P = 0.91 P = 0.96
Age at diagnosis of LRR/NP SCCHN 1.4 (0.84–2.36) 1.01 (0.52–2.03) 1.62 (0.97–2.77)
< 60 vs. ≥ 60 P = 0.2 P = 0.97 P = 0.07
Sex 0.92 (0.52–1.71) 0.53 (0.27–1.15) 0.98 (0.54–1.91)
Male vs. Female P = 0.78 P = 0.1 P = 0.95
Tobacco abuse 0.67 (0.86–2.72) 1.84 (0.26–1.12) 0.82 (0.71–2.16)
< 20 PY vs. > 20 PY P = 0.16 P = 0.1 P = 0.48
Post-operative vs. Definitive RRT 0.67 (0.4–1.11) 0.62 (0.31–1.23) 0.67 (0.4–1.1)
P = 0.12 P = 0.17 P = 0.12
Time since primary SCCHN 0.77 (0.44–1.3) 1.19 (0.43–1.73) 0.79 (0.75–2.18)
< 24 mos vs. ≥ 24 mos P = 0.33 P = 0.63 P = 0.39
Chemotherapy vs. no chemotherapy
with RRT
1.47 (0.82–2.84) 2.43 (1.02–7.16) 1.12 (0.66–1.98)
P = 0.2 P = 0.04 P = 0.68
Platinum vs. cetuximab with RRT 0.65 (0.36–1.22) 0.4 (0.19–0.86) 0.65 (0.33–1.31)
P = 0.18 P = 0.02 P = 0.22
IMRT versus other 0.99 (0.4–3.32) 2.03 (0.43–36.2) 1.21 (0.49–4.04)
P = 0.99 P = 0.44 P = 0.71
CI confidence interval, HR hazard ratio, IMRT intensity modulated radiation therapy, LRR loco-regionally recurrent, NP new primary, NR not reached, PY pack-years,
RRT reirradiation therapy, SCCHN squamous cell carcinoma of head and neck
Fig. 2 Kaplan-Meier plot of loco-regional relapse free survival among LRR/NP SCCHN patients treated with PRRT or DRRT at Mayo Clinic
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spinal cord injuries. Long term toxicity data are further
summarized in Table 4. Late toxicity was incompletely
documented in the medical record and could not be re-
ported in this analysis.
Discussion
Patients previously treated for SCCHN are at risk for
new primary cancers in the treatment volume due to
“field cancerization” effect, and most cases of LRR/NP
SCCHN occur in or near areas previously treated with
surgery and/or radiotherapy [5]. LRR/NP SCCHN there-
fore is less amenable to cure with surgery and/or RRT,
owing to radiation resistance mechanisms in the new or
recurrent cancer as well as the local morbidity imposed
by re-treatment [5]. Here we report the outcomes of
LRR/NP SCCHN patients treated with RRT at Mayo
Clinic between 2003 and 2011. The long term outcomes
of our patients are similar if not superior to previously
reported findings from other groups. Our analysis there-
fore confirms several key previously published findings.
First, our results confirm that RRT can achieve long-
term disease control in a modest percentage of patients
with LRR/NP SCCHN. With a median follow-up of ap-
proximately 6.5 years, 23 % of patients in our series were
alive at last follow-up; 50 % were alive at 2 years. These
data support the use of RRT for LRR/NP SCCHN pa-
tients as a salvage treatment approach despite its known
risk of side effects.
Outcomes of patients treated with either PRRT or
DRRT in our series appear superior to those from previ-
ous reports. The 2-year OS for PRRT-treated patients we
observed is higher than the 45 % 2-year OS observed in
the prospective phase III study of salvage surgery with
or without post-operative RRT with chemotherapy con-
ducted by the Groupe d’Etude des Tumeurs de la Tête
Et du Cou and Groupe d’Oncologie Radiothérapie Tête
et Cou (GORTEC) groups [6]. Our 2-year OS for DRRT-
treated patients (48 %) is better than that observed in
the prospective RTOG 9610 trial of 4 weekly cycles of 5-
fluorouracil/hydroxyurea with 60 Gy at 1.5 Gy in twice-
daily fractions, which demonstrated 2-year OS of 15.2 %
(95 % CI, 7.3–23.1 %) [7]. The 2-year OS with DRRT re-
ported here also is better than was found in the pro-
spective RTOG 9911 trial of cisplatin plus paclitaxel IV
daily times 5 days, every 2 weeks, for 4 courses with
split-course RRT, 60 Gy total dose, 1.5 Gy BID times
5 days, every 2 weeks, times 4 courses. That study dem-
onstrated a 2-year OS of 25.9 % (95 % CI, 17.3–35.3 %),
and also found inferior median OS for those treated
more than 36 months after first radiation (10.8 months)
versus 14.1 months if treated within 36 months of first
radiation, a finding which we could not confirm [8].
Both RTOG studies used radiation treatment regimens
other than conventional fractionation and RTOG 9610
did not use IMRT, which was used for the majority of
patients in our study, and might contribute to the differ-
ence in OS we observed. IMRT has been shown to im-
prove LRFS and OS in the primary treatment of SCCHN
and in LRR/NP SCCHN [9, 10]. Lee and others [9]
found that among patients treated with RRT using con-
ventional techniques (31 patients) versus IMRT (74 pa-
tients) between 1996 and 2005, LRFS was 52 % at
2 years with IMRT versus 20 % with conventional RRT
(p < 0.001; on univariate analysis, OS was superior with
IMRT (HR for death 0.57, 95 % CI, 0-35-0.93, p = 0.03).
We could not confirm this finding on univariate analysis,
although the small numbers of patients treated with
RRT technique other than IMRT in our series probably
limits our ability to detect a survival difference by tech-
nique. The demographics of our patient population mir-
rored the study population of the RTOG 9610 and
RTOG 9911 studies in terms of age (median 62 and
60 years, respectively), gender (over 75 % male in both
studies) and time since primary radiation (median
2.5 years and 39.6 months, respectively). Therefore, the
differences in outcomes we observed are not explained
by differences in these factors.
The 2-year OS of our DRRT-treated patients also ap-
pears superior to outcomes of DRRT-treated patients re-
ported in many studies published since 2000 [7, 8, 11–
27]. In these studies, OS at 2-years of 20 % or less was
reported in 9 of 19 series; only 1 report [22] found a
2 year OS similar to the Mayo Clinic experience
(45.1 %). In one of the largest series of DRRT outcomes
reported to date, De Crevoisier and others reported a 2-
year OS of 21 % (95 % CI, 15–29 %) [28]. We used a
higher median radiation dose than was given in most of
Table 4 Long term complications reported among LRR/NP
SCCHN patients undergoing reirradiation at Mayo Clinic alive at
last follow-up, by treatment modality
Surgery/PRRT DRRT
n (%) n (%)
Carotid artery aneurysm 1 (2) 0
Dysphagia 2 (5) 0
Esophageal stenosis 1 (2) 1 (3)
Feeding tube at last f/u 1 (2) 2 (5)
Hypothyroid 1 (2) 0
Impaired shoulder ROM 2 (5) 0
Ischemic retinopathy 1 (2) 0
None reported 5 (12) 1 (3)
Osteoradionecrosis 1 (2) 1 (3)
Soft tissue fibrosis 1 (2) 0
Tracheoesophageal fistula 1 (2) 0
Xerostomia 2 (5) 2 (5)
ROM range of motion
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the series reporting 2-year OS ≤ 20 %, where radiation
doses ranged from 34 to 60 Gy (8 of 9 studies). Higher
RRT doses may be required to achieve long term disease
control, a hypothesis supported by a previous retrospect-
ive analysis of 103 patients undergoing RRT, in which
RRT dose > 50 Gy was associated with improved survival
[29]. Our finding that PRRT-treated patients treated with
at least 60 Gy of RRT had a trend toward improved OS
compared to those treated with lower PRRT doses also
lends support to this hypothesis. However, published evi-
dence to the contrary exists, as a prospective phase I
study by Seiwert et al. found 2-year OS of just 17.2 %
despite a median RRT dose of 70 Gy [21]. In the current
era, PET/CT staging routinely is used to better select ap-
propriate patients for RRT, thereby potentially favorably
impacting the outcomes we report in comparison to
older series.
Surgical salvage is believed to be the most effective
treatment for LRR SCCHN, a conclusion based on a
meta-analysis of 32 published reports of salvage surgery
in which 5 year OS of 39 % was reported [30]. Although
patients in our study treated with surgical salvage and
PRRT did not have a significantly different OS from
DRRT-treated patients, we did observe a trend toward
improved OS among PRRT patients. The 2-year OS of
PRRT patients in our report (53 %) mirrors that found
in multiple previous reports, where OS at 2 years ranges
from 21 to 81 % [11, 12, 31–37]. This finding probably is
explained by selection bias: patients selected for salvage
surgery generally are in better overall health and have
smaller tumors, potentially creating a selection bias in
favor of PRRT compared to DRRT. Greater use of cetux-
imab than cisplatin with DRRT as observed in our series
also suggests selection bias of patients with more comor-
bidities and/or poorer functional status for DRRT in lieu
of surgery/PRRT, potentially skewing the survival out-
comes of DRRT-treated patients.
We found no significant impact on survival outcomes
with the addition of concurrent systemic chemotherapy
to RRT. A large percentage of LRR/NP SCCHN patients
in our cohort received systemic therapy, typically cis-
platin with PRRT and cetuximab with DRRT, but the
choice of platinum versus cetuximab did not impact OS
on univariate analysis. Receipt of any form of chemo-
therapy was associated with inferior LRFS. We suspect
this finding also relates to a selection bias, wherein pa-
tients with higher risk, more advanced LRR/NP SCCHN
were chosen for “aggressive” treatment with chemother-
apy and RRT. Indeed, a large percentage of patients with
positive surgical margins received chemotherapy, and
the majority of patients treated with concurrent chemo-
therapy also had nodal involvement. Therefore, the in-
ferior LRFS observed with chemotherapy plus RRT
compared to RRT alone most likely was due to disease
related factors, rather than a deleterious effect of chemo-
therapy on RRT. Given that randomized studies of
chemotherapy with radiation for newly diagnosed, previ-
ously untreated SCCHN show a survival benefit of ap-
proximately 6 % [38], it is not surprising that no OS
difference was found between patients treated with RRT
and chemotherapy versus RRT alone in this retrospective
series with a smaller number of patients.
The incidence of long-term, serious adverse effects
from RRT in our study was low. Inadequate documenta-
tion and patients lost to long term follow-up very likely
lead to an underestimation of the late side effects of
RRT. Of those patients alive at last follow-up, few ser-
ious adverse events had been recorded, but these may be
underestimated due to the lack of systematic documen-
tation of adverse events as would have occurred had this
been a prospective trial. The vast majority of toxicities
were limited in duration to the period of RRT and subse-
quently resolved. In contrast, prospective trials of RRT
have shown higher rates of late grade 3–4 toxicity.
RTOG 9610 reported 19.4 % late (>90 days) grade 3 and
3 % late grade 4 toxicity, mostly pharyngeal and esopha-
geal, including 2 fatal hemorrhages [7]. RTOG 9911 re-
ported approximately 17 % of patients having grade 3
and 17 % grade 4 late toxicity, with 3 of 8 treatment re-
lated deaths due to carotid artery hemorrhage [8]. An-
other prospective phase I/II trial of low dose daily
cisplatin/paclitaxel with split course RRT reported 34 %
of patients with long term toxicities including 2 each of
ORN, carotid artery hemorrhage, trismus and fistula for-
mation [18]. Late grade 3 toxicity rates as high as 47.5 %
have been reported in retrospective series, some of
which did not use IMRT [29]. A pooled analysis found a
rate of carotid artery rupture of 2.6 % among 1554 pa-
tients in 27 published articles, with 76 % of events being
fatal [39]. Conventional or hyperfractionated techniques
as opposed to accelerated hyperfractionation, and use of
IMRT versus 3D-conformal RT may reduce serious long
term side effects of RRT [39, 40]. The low rates of ser-
ious long term adverse effects from RRT we report could
be due to the use of a hyperfractionated schedule with
IMRT in the majority of patients, but again it would be
difficult to make firm conclusions given the small sam-
ple size and high chance of underreporting of toxicities.
Stereotactic body radiotherapy (SBRT) has gained at-
tention in recent years as a viable alternative to conven-
tional RT for patients with LRR/NP SCCHN. In
comparison to conventional RT, which treats larger vol-
umes over more elapsed days using conventional dose
fractionation, SBRT treats smaller volumes, better spares
normal tissues, delivers greater biological dose, and is
given over 5 or fewer elapsed treatment days. Disadvan-
tages of SBRT include more complex planning and
higher doses per treatment to previously irradiated
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tissues, potentially increasing toxicity depending on the
tissue type. Several groups have published their experi-
ence with SBRT for LRR/NP SCCHN. In these series,
median RT doses have ranged from 24 to 48 Gy. Overall
response rates ranging from 58.1 to 81 % and median
OS of 6.7 to 16.2 months have been reported. Up to
17.8 % rates of grade 3 toxicity, including fistula and ca-
rotid artery hemorrhage have been observed [41]. A re-
cent prospective phase II study of cetuximab with SBRT
(consisting of 40–44 Gy in 5 fractions on alternating
days over 1–2 weeks) showed a 51 % complete and par-
tial response rate and 14 % with stable disease. Median
OS was 10 months (95 % CI, 7–16 months), and 37 %
were free of loco-regional progression at 1 year (95 %
CI, 23–53 %). Observed toxicity included a 6 % rate of
late grade 3 toxicity (2 patients with fistula, 1 patient
with dysphagia, 1 patient with an arterial bleed, but no
incidence of carotid artery hemorrhage). Quality of life
was stable or improved compared to baseline in 62 % of
patients [42]. Early results of SBRT are encouraging, but
prospective trials comparing outcomes with SBRT to
3D-conformal RT or IMRT are lacking. Several trials of
SBRT for LRR/NP SCCHN are ongoing.
The outcomes of RRT for LRR/NP SCCHN in our study
compare favorably to those reported in the literature.
However, as with any retrospective review, there are sev-
eral limitations to our study. The variety of LRR/NP sites
among patients included in the series and the varying
radiotherapy techniques and chemotherapy regimens used
limit our ability to determine if RRT is more beneficial for
some LRR/NP sites than others or to make firm conclu-
sions about the optimal dose, volume and technique of
RRT to use and which chemotherapy agent (if any) maxi-
mizes radiosensitization. The survival outcomes and tox-
icity rates we report may contain inaccuracies due to loss
of patients to long term follow up, and our outcomes may
differ from other reports owing to strict patient selection
criteria and routine use of PET/CT for staging. Despite
these limitations, the outcomes of patients with LRR/NP
SCCHN treated with RRT at Mayo Clinic demonstrate
that a subset of patients can achieve long-term survival
with acceptable toxicities. Studies of molecular markers to
guide treatment in this heterogeneous group of patients
are desperately needed. The use of particle beam radio-
therapy may improve sparing of normal tissues and allow
radiation dose escalation. We plan to explore the role of
proton beam radiotherapy for LRR/NP SCCHN; these
data presented here will serve as a basis for comparison of
outcomes with photon-based radiotherapy to proton
radiotherapy in this patient population.
Conclusions
In conclusion, patients with LRR/NP SCCHN require
treatment to spare them from morbidity of their disease
and to offer them the best hope of long term survival.
Such patients should be offered surgical salvage when
appropriate with or without RRT or DRRT for non-
surgical candidates, in keeping with the American Col-
lege of Radiology Appropriateness Criteria for retreat-
ment of recurrent SCCHN [43]. Higher doses of
radiation likely are required to produce long term dis-
ease control. The roles of treatment modalities such as
SBRT and proton beam therapy need to be better de-
fined by prospective trials. Ongoing research into the
best radiation technique and most effective systemic
chemotherapeutic agents will clarify treatment algo-
rithms for LRR/NP SCCHN patients in coming years.
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